Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-cfpbc Total loading time: 0 Render date: 2024-04-24T19:58:49.574Z Has data issue: false hasContentIssue false

Chapter 15 - The use of botulinum neurotoxin in spastic infantile cerebral palsy

Published online by Cambridge University Press:  05 February 2014

Ann Tilton
Affiliation:
Louisiana State University Health Sciences Center, New Orleans, LA, USA
H. Kerr Graham
Affiliation:
University of Melbourne, Royal Children’s Hospital, Parkville, Victoria, Australia
Daniel Truong
Affiliation:
The Parkinson’s and Movement Disorders Institute, Fountain Valley, California
Dirk Dressler
Affiliation:
Department of Neurology, Hannover University Medical School
Mark Hallett
Affiliation:
George Washington University School of Medicine and Health Sciences, Washington, DC
Christopher Zachary
Affiliation:
Department of Dermatology, University of California, Irvine
Get access

Summary

Introduction

Cerebral palsy is not a specific disease but a clinical syndrome caused by a non-progressive injury to the developing brain that results in a disorder of movement and posture that is permanent but not unchanging. It is the most common cause of physical disability affecting children in developed countries. The incidence is steady in most countries at approximately 2 per 1000 live births. The prevalence of cerebral palsy is much higher in children with birth weight under 1500 g and in those born earlier than 28 weeks of gestation. The location, timing and severity of the brain lesion are extremely variable, which results in many different clinical presentations. Despite the static nature of the brain injury, the majority of children with cerebral palsy develop progressive musculoskeletal problems such as posturing and muscle contractures (Koman et al., 2004). Additionally, as pointed out in an expert consensus on cerebral palsy, it is important to recognize that there are also frequent yet inconsistent disturbances of sensation, cognition, communication and perception; abnormalities of behavior; and seizures (Bax et al., 2005).

Classification

Cerebral palsy may be classified according to the cause of the brain lesion (when this is known), and the location of the brain lesion as noted on imaging such as MRI or CT. Clinically more useful classification schemes are based on the type of movement disorder, the distribution of the movement disorder (Box 15.1) and the gross motor function of the child.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bax, M, Goldstein, M, Rosenbaum, P et al. (2005). Proposed definition and classification of cerebral palsy, Dev Med Child Neurol, 47, 571–6.CrossRefGoogle ScholarPubMed
Delgado, MR, Hirtz, D, Aisen, M et al. (2010). Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review). Neurology, 74, 336–43.CrossRefGoogle Scholar
Fehlings, D, Novak, I, Berweck, S (2010). Botulinum toxin assessment, intervention and follow-up for paediatric upper limb hypertonicity: international consensus statement. Eur J Paediatr Neurol, 17, 36–56.Google ScholarPubMed
Heinen, F, Desloovere, K, Schroeder, AS et al. (2010). The updated European Consensus 2009 on the use of botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol, 14, 45–66.CrossRefGoogle ScholarPubMed
Koman, LA, Smith, BP, Shilt, JS (2004). Cerebral palsy. Lancet, 363, 1619–31.CrossRefGoogle ScholarPubMed
Palisano, RJ, Rosenbaum, P, Walter, S et al. (1997). Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol, 45,113–20.CrossRefGoogle Scholar
Russman, BS, Tilton, AH, Gormley, ME (2002). Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. In Mayer, NH, Simpson, DM (eds.) Spasticity: Etiology, Evaluation, Management, and the Role of Botulinum Toxin. New York, WE MOVE, pp. 134–43.Google Scholar
Winters, TF, Gage, JR, Hicks, R (1987). Gait patterns in spastic hemiplegia in children and young adults. J Bone Joint Surg, 69, 437–41.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×